Description Results NMA

     

  • Group by...

pdf
pathology Demonstrated benefit and harm k      
diabetes type 2

versus placebo

semaglutide superior to placebo in terms of CV events in SUSTAIN 6, 2016

semaglutide inferior to placebo in terms of Retinopathy in SUSTAIN 6, 2016

1 trialmeta-analysis



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons